Medication alternatives · FDA-sourced
Advair Diskus Alternatives and FDA-Approved Generic Equivalent
Wixela Inhub contains the same active ingredients as Advair Diskus and is FDA-designated as therapeutically equivalent at matching 100/50, 250/50, and 500/50 strengths. This page separates direct equivalents from other types of clinical, formulary, and device alternatives.
Direct equivalent
Matching Advair Diskus and Wixela Inhub strengths
FDA determined Wixela Inhub to be bioequivalent and therapeutically equivalent to Advair Diskus at the three matching strengths below. Different strengths are not presented as direct equivalents.
Advair Diskus
100/50 mcg — 1 inhalation twice daily
Wixela Inhub
100/50 mcg — 1 inhalation twice daily
Advair Diskus
250/50 mcg — 1 inhalation twice daily
Wixela Inhub
250/50 mcg — 1 inhalation twice daily
Advair Diskus
500/50 mcg — 1 inhalation twice daily
Wixela Inhub
500/50 mcg — 1 inhalation twice daily
What “equivalent” means here
This page uses the FDA therapeutic-equivalence designation only for matching strengths. It does not label different doses, different drug combinations, formulary choices, or nebulized regimens as interchangeable.
Device counseling still matters
Diskus and Inhub are different dry-powder inhaler devices. A prescriber or pharmacist should address the prescription, coverage, device technique, and patient-specific considerations.
Common questions
Advair Diskus and Wixela Inhub FAQ
Is Wixela Inhub equivalent to Advair Diskus?
Yes, at matching strengths. FDA determined Wixela Inhub 100/50, 250/50, and 500/50 to be bioequivalent and therapeutically equivalent to the corresponding Advair Diskus strengths.
Which Advair Diskus and Wixela Inhub strengths match?
The matching pairs are 100/50 to 100/50, 250/50 to 250/50, and 500/50 to 500/50. This database does not treat different strengths as direct equivalents.
Are the Diskus and Inhub devices identical?
No. Both deliver dry-powder fluticasone propionate and salmeterol, but they are different inhaler devices. Patients should receive instructions for the device they are dispensed.
Which strength is labeled for COPD maintenance treatment?
The prescribing information for both products identifies 250/50 mcg, one inhalation twice daily, as the labeled COPD maintenance dosage.
Should I switch inhalers without speaking to a clinician?
No. FDA therapeutic-equivalence information does not replace professional responsibility or patient-specific counseling. A prescriber or pharmacist should address the prescription, device technique, coverage, and individual clinical considerations.
Primary sources
Evidence used for this page
DailyMed / U.S. National Library of Medicine
ADVAIR DISKUS Prescribing Information
Supports Advair Diskus ingredients, strengths, labeled uses, and administration.
DailyMed / U.S. National Library of Medicine
WIXELA INHUB Prescribing Information
Supports Wixela Inhub ingredients, strengths, labeled uses, and administration.
U.S. Food and Drug Administration
ANDA 208891 Approval — Wixela Inhub
Supports the matching-strength FDA therapeutic-equivalence statement.
U.S. Food and Drug Administration
Orange Book Preface
Supports FDA therapeutic-equivalence definitions and practitioner responsibilities.
Reviewed by PulmTools Editorial Review on August 27, 2026.
Explore respiratory pharmacology →